In a nutshell This study investigated whether local ablative methods (LAT; non-invasive procedures) of treatment can be used in patients with colorectal cancer that are older or have other medical conditions. Researchers suggested that these procedures may be performed safely in these patients. Some background Age is a major risk factor for colorectal...
Read MoreConfined or spread disease-Spread with distant metastasis Posts on Medivizor
Effect of cancer medications nivolumab and ipilimumab on melanoma which has spread to the brain
In a nutshell This study looked at two medications for treatment of melanoma, nivolumab (Opdivo) and ipilimumab (Yervoy), and analysed how well they worked in patients who have melanoma which has spread to the brain. The study found that the combination of nivolumab and ipilimumab had significant clinical benefit in patients with melanoma with brain...
Read MoreLooking for patients with triple negative inoperable breast cancer to test a new treatment option atezolizumab
In a nutshell This trial is examining the effectiveness of atezolizumab (Tecentriq) when used with chemotherapy in patients with inoperable, recurrent triple-negative breast cancer. The main outcome to be measured will be the overall survival (time from treatment until death from any cause) of participants. The...
Read MoreLooking for patients with HER2 negative HR positive advanced breast cancer to test tesetaxel
In a nutshell This trial is examining the effectiveness of tesetaxel plus a reduced dose of capecitabine for hormone receptor (HR) positive/HER2 negative advanced breast cancer. The main outcome to be measured will be progression free survival (time from treatment until disease progression). The details Breast cancer is classified into...
Read MoreFulvestrant compared to aromatase inhibitors in post-menopausal women with HR+ advanced breast cancer
In a nutshell This study aimed to look at the safety and effectiveness of fulvestrant (Faslodex) compared to aromatase inhibitors in post-menopausal women with hormone receptor-positive (HR+) breast cancer. The authors found that fulvestrant was a safe and effective treatment in these patients when compared to aromatase inhibitors. Some...
Read MoreNew melanoma therapies are associated with improved survival rates
In a nutshell This study examined the survival rates of melanoma patients with brain metastasis treated with new therapies. Researchers concluded that PD-1 agents are associated with improved survival outcomes. Some background More than 50% of melanoma patients develop brain metastasis (cancer spread), with an overall survival of 17 to 22 weeks....
Read MoreVitamin D is associated with melanoma outcomes
In a nutshell This study investigated if low levels of vitamin D are associated with worse melanoma prognosis. Researchers suggested that low levels of vitamin D are associated with worse outcomes in metastatic (spread to other parts of the body) melanoma. Some background Recent studies have suggested that a low vitamin D level (less than 20...
Read MorePanitumumab injections to treat metastatic colorectal cancer
In a nutshell This study investigated the effectiveness and safety of short 15-minute panitumumab (Vectibix) injections. Researchers suggested that these injections were well tolerated with manageable side effects. Some background Panitumumab is a therapy that targets the EFGR receptor on cancer cells. This blocks cell growth which results in cell...
Read MoreLooking for patients with metastatic triple negative breast cancer to examine the effect of Nivolumab in combination with Cabozantinib
In a nutshell This trial is examining the effectiveness of nivolumab (Opdivo) in combination with cabozantinib (Cometriq) for metastatic triple-negative breast cancer (cancer that is not dependent on hormones or HER2 for growth). The outcome to be measured will be the response rate of the cancer to this treatment. This study is...
Read MoreLooking for patients with HER2-positive inoperable breast cancer to examine the efficacy and safety of antibody-drug conjugate SYD985
In a nutshell This trial is examining the effectiveness of the antibody-drug conjugate SYD985 for HER2-positive inoperable advanced breast cancer. The main outcome to be measured will be time from treatment until disease progression or the time taken for tumor growth or spread. This study is being conducted in Baltimore, Maryland, inthe United...
Read MoreLooking for advanced melanoma patients to test the safety and effectiveness of a combined treatment
In a nutshell This phase 2 trial aims to test the safety and effectiveness of the combined treatment with pembrolizumab (Keytruda), trametinib (Mekinist) and dabrafenib (Tafinlar) for advanced melanoma. The main outcomes of this trial include overall survival (time from treatment until death from any cause), side effects and response rate to the...
Read MoreVemurafenib combined with cobimetinib is an effective treatment option for advanced melanoma
In a nutshell This study examined the effectiveness of treatment with vemurafenib (Zelboraf) and cobimetinib (Cotellic) in metastatic (spread to other parts of the body) melanoma. Researchers suggested that this combination improves treatment outcomes. Some background PD-L1 is a protein present in the immune system that helps attacking cancer...
Read More
